Form 4: Arcellx Director Kristin Myers Reports Merger-Related Transactions

Arcellx, Inc. Director Kristin Myers has reported transactions related to the company's merger with Gilead Sciences, Inc., detailing the conversion of stock options.

Summary

• This filing is a Form 4, reporting changes in beneficial ownership of securities for Arcellx, Inc. Director Kristin Myers.
• The earliest transaction date reported is April 28, 2026.
• The filing details the conversion of stock options into cash payments and contingent value rights as a result of the merger between Arcellx, Inc. and Gilead Sciences, Inc. (via its subsidiary Ravens Sub, Inc.).
• Specifically, stock options with an exercise price less than $115 per share were canceled and converted into a cash payment (Closing Amount minus exercise price, multiplied by the number of shares) and one contingent value right per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on the mechanics of a completed merger's impact on executive compensation rather than new operational or financial performance.

Positives

• The merger with Gilead Sciences, Inc. provides a positive outcome for option holders, converting their options into cash and contingent value rights.
• The structure of the conversion ensures that option holders receive value for their vested and unvested options, provided the exercise price is below the $115 Closing Amount.

Negatives

• Outstanding stock options with an exercise price of $115 or higher per share would not receive a cash payment, though they would still receive contingent value rights.
• The cancellation of stock options represents a change from direct equity ownership to a cash and contingent value right structure.

Risks

• The value of the contingent value rights is dependent on future events and milestones related to Arcellx's pipeline, introducing uncertainty.
• The filing does not detail the specific terms or potential value of the contingent value rights, which could be a risk for stakeholders if they are not substantial.

Future Outlook

The future outlook for Arcellx is now tied to its integration with Gilead Sciences and the performance of its pipeline, as reflected in the contingent value rights issued to option holders.

Management Comments

• The filing is a standard disclosure of transactions by a director following a merger, indicating adherence to regulatory requirements.
• The conversion of options is a direct consequence of the merger agreement, designed to provide value to option holders.

Industry Context

StockSavvy.ai notes that this Form 4 filing is a standard post-merger disclosure, reflecting the common practice of converting equity awards into cash and contingent value rights when a company is acquired. This is typical in the biotechnology and pharmaceutical sectors where pipeline development is key.

Stakeholder Impact

• Shareholders of Arcellx will now hold shares in Gilead Sciences, Inc. or have received cash and contingent value rights.
• Option holders have had their options converted into cash payments and contingent value rights, with the value dependent on the merger terms and future performance.
• Employees of Arcellx will now be employees of Gilead Sciences, Inc., subject to new employment terms and conditions.

Next Steps

• Shareholders and option holders will await further information regarding the value and payout of the contingent value rights.
• Arcellx will operate as a wholly owned subsidiary of Gilead Sciences, Inc.

Key Dates

Keywords

Arcellx, ACLX, Form 4, Kristin Myers, Gilead Sciences, Merger, Stock Options, Beneficial Ownership, SEC Filing, Contingent Value Rights